1204772-01-9

Basic information

• Product Name: 2-(3-phenyl-6-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)thiazole-4-carboxylic acid
• Synonyms: 2-(3-phenyl-6-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)thiazole-4-carboxylic acid
• CAS NO: 1204772-01-9
• Molecular Weight: 393.389
• Mol File: 1204772-01-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(3-phenyl-6-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)thiazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-phenyl-6-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)thiazole-4-carboxylic acid(1204772-01-9)
• EPA Substance Registry System: 2-(3-phenyl-6-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)thiazole-4-carboxylic acid(1204772-01-9)

Safety Data

• Hazardous Substances Data: 1204772-01-9(Hazardous Substances Data)

Upstream product

• 585-36-4 3-(trifluoromethyl)cyclohexanone 
• 98-88-4 benzoyl chloride 

Relevant articles and documents

Discovery of a novel 2-(1H-pyrazolo[3,4-b]pyridin-1-yl)thiazole derivative as an EP1 receptor antagonist and in vivo studies in a bone fracture model

We describe a medicinal chemistry approach to the discovery of a novel EP1 antagonist exhibiting high potency and good pharmacokinetics. Our starting point is 1, an EP1 receptor antagonist that exhibits pharmacological efficacy in cystometry models following intravenous administration. Despite its good potency in vitro, the high lipophilicity of 1 is a concern in long-term in vivo studies. Further medicinal chemistry efforts identified 4 as an improved lead compound with good in vitro ADME profile applicable to long term in vivo studies. A rat fracture study was conducted with 4 for 4 weeks to validate its utility in bone fracture healing. The results suggest that this EP1 receptor antagonist stimulates callus formation and thus 4 has potential for enhancing fracture healing.